Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $78.00.

Several research analysts have recently commented on the stock. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Mizuho increased their price target on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Truist Financial boosted their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th.

Lantheus Trading Up 0.5%

NASDAQ:LNTH opened at $67.51 on Friday. The company has a market cap of $4.48 billion, a PE ratio of 28.37 and a beta of -0.11. The business’s 50 day moving average is $63.52 and its two-hundred day moving average is $60.57. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.27. The business had revenue of $384.01 million for the quarter, compared to analyst estimates of $363.42 million. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, analysts predict that Lantheus will post 6.01 EPS for the current year.

Institutional Trading of Lantheus

A number of large investors have recently modified their holdings of LNTH. Hantz Financial Services Inc. boosted its position in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus during the second quarter valued at about $26,000. First Horizon Corp acquired a new stake in Lantheus in the third quarter worth about $26,000. Osterweis Capital Management Inc. acquired a new stake in Lantheus in the second quarter worth about $36,000. Finally, Farther Finance Advisors LLC grew its position in Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 275 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.